The compound has been investigated in the patent literature for its anxiolytic Attributes and decreased sedative, hypnotic, and ataxic facet-outcomes, but it does not appear to be accredited for clinical use. ?ukasik-G?ebocka et alThe effects had been usually as compared to those of flunitrazepam (Rohypnol), but most seemed to concur that flubromaz